Back to Search

GARY SHAPIRO, MD

MD

Orthopaedic Surgery Physician

NPI: 1881649689IndividualAccepts Medicare

Specialties, Licenses & Credentials

Orthopaedic Surgery PhysicianPrimary

Orthopaedic Surgery

Code: 207X00000X

036-108112(IL)

CMS Specialties

PrimaryORTHOPEDIC SURGERY

Education

NEW YORK UNIVERSITY SCHOOL OF MEDICINE

Class of 1996

Research & Publications (20)

The use of a constrained acetabular component for recurrent dislocation.
PMID 12728414·J Arthroplasty·2003
8-other
Recombinant adenoviral vectors can induce expression of p73 via the E4-orf6/7 protein.
PMID 16699015·J Virol·2006
7-preclinical
Are there limits to oncology care? (Futility).
PMID 10650480·Cancer Treat Res·2000
8-other
Targeting retinal and choroid neovascularization using the small molecule inhibitor carboxyamidotriazole.
PMID 19679174·Brain Res Bull·2010
7-preclinical
HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy.
PMID 19122144·Proc Natl Acad Sci U S A·2009
7-preclinical
Clinical diagnosis of sleep apnea based on single night of polysomnography vs. two nights of polysomnography.
PMID 19067010·Sleep Breath·2009
8-other
Mirtazapine, a sedating antidepressant, and improved driving safety in patients with major depressive disorder: a prospective, randomized trial of 28 patients.
PMID 19192466·J Clin Psychiatry·2009
4-observational
A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors.
PMID 19318484·Clin Cancer Res·2009
3-trial
Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions.
PMID 19451690·J Clin Invest·2009
7-preclinical
Heat shock protein 90 inhibition in lung cancer.
PMID 18520302·J Thorac Oncol·2008
6-review
Summary statement novel agents in the treatment of lung cancer: Fifth Cambridge Conference assessing opportunities for combination therapy.
PMID 18520291·J Thorac Oncol·2008
8-other
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models.
PMID 18408761·Oncogene·2008
7-preclinical
Epoetin-alpha: preserving kidney function via attenuation of polymorphonuclear leukocyte priming.
PMID 18548979·Isr Med Assoc J·2008
3-trial
Allergen skin tests and free IgE levels during reduction and cessation of omalizumab therapy.
PMID 18269927·J Allergy Clin Immunol·2008
4-observational
Phase I/II study of vinorelbine and exisulind as first-line treatment of advanced non-small cell lung cancer in patients at least 70 years old: a wisconsin oncology network study.
PMID 18758305·J Thorac Oncol·2008
3-trial
Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance.
PMID 18632637·Cancer Res·2008
7-preclinical
Are there limits to oncology care? (Futility).
PMID 18283774·Cancer Treat Res·2008
8-other
Phase I study of flavopiridol in combination with Paclitaxel and Carboplatin in patients with non-small-cell lung cancer.
PMID 18621626·Clin Lung Cancer·2008
3-trial
Early detection of erlotinib treatment response in NSCLC by 3'-deoxy-3'-[F]-fluoro-L-thymidine ([F]FLT) positron emission tomography (PET).
PMID 19079597·PLoS One·2008
7-preclinical
Nonpeptide somatostatin receptor agonists specifically target ocular neovascularization via the somatostatin type 2 receptor.
PMID 18599562·Invest Ophthalmol Vis Sci·2008
4-observational

Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.

Contact & Hours

Address
2401 RAVINE WAY, SUITE 200
GLENVIEW, IL 60025

Location

Practice Location

2401 RAVINE WAY, GLENVIEW, IL
(847) 998-5680

Quick Facts

NPI
1881649689
Entity Type
Individual
Gender
Male
Medicare
Accepted
Specialties
1
Locations
1
Years in Practice
30
Publications
20

Are you this provider?

Claim Your Profile